Deciphera Pharmaceuticals Inc

+0.74 (+4.04%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.27B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$33.15 Million
Adjusted EPS-$0.58
See more estimates
10-Day MA$18.37
50-Day MA$16.58
200-Day MA$11.77
See more pivots

Deciphera Pharmaceuticals Inc Stock, NASDAQ:DCPH

200 Smith Street, 6th floor, Waltham, Massachusetts 02451
United States of America
Phone: +1.781.209.6400
Number of Employees: 280


Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.